The trial will assess Aldeyra’s ADX‑629 to treat atopic dermatitis. Credit: James Heilman, MD/ commons.wikimedia.org.

Aldeyra Therapeutics has enrolled the first participant in the Phase II clinical trial of investigational new drug, ADX‑629, to treat atopic dermatitis.

The two-part, adaptive, multicentre Phase II trial has been designed for assessing the efficacy and safety of ADX‑629 alone and along with standard of care in mild, moderate, or severe atopic dermatitis adult patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Nearly 10 participants will receive open-label ADX‑629 twice-a-day for 90 days in Part 1 of the trial.

Improvement in Investigator Global Assessment and Eczema Area and Severity Index scores will be some of the trial’s outcomes.

In Part 2, participants will be randomised to receive either ADX‑629 or placebo treatment twice-a-day for 90 days.

See Also:

The company expects to receive top-line results from Part 1 in the second half of this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Aldeyra Therapeutics CEO and president Todd Brady said: “Atopic dermatitis, a chronic hypersensitivity condition characterised by dry, itchy, and inflamed skin, affects an estimated 16.5 million adults and more than 9.6 million children in the United States.

“ADX‑629, if approved, would be the first RASP modulator and one of the few orally administered therapies indicated for the treatment of atopic dermatitis.”

The company stated that ADX‑629 is also currently being assessed in Phase II clinical trials to treat Sjögren-Larsson Syndrome, chronic cough, and idiopathic nephrotic syndrome.

It expects to obtain top-line results from the chronic cough trial in the first half of this year.

In the second half, a Phase II clinical trial of ADX-629 to treat moderate alcohol-associated hepatitis is anticipated to commence.